KORU Medical Systems
KRMDKORU Medical Systems develops and commercializes innovative, patient-centric subcutaneous infusion solutions for large-volume drug delivery.
Earnings
Next report
Nov 11, 2026 (in 2 months)Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
KORU Medical Systems develops and commercializes innovative, patient-centric subcutaneous infusion solutions for large-volume drug delivery. The company specializes in mechanical infusion systems that enable patients to self-administer life-saving therapies, such as immunoglobulin, in home or alternate site settings. Its core value proposition centers on improving patient quality of life through portable, easy-to-use, and cost-effective alternatives to intravenous hospital-based treatments.
KORU is a leading provider of large-volume subcutaneous infusion systems and maintains the market-leading delivery system in the U.S. for SCIg treatments.
FAQ
- What is KORU Medical Systems's market cap?
- KORU Medical Systems (KRMD) has a market capitalization of $147.8M and trades on NASDAQ.
- What is KORU Medical Systems's revenue and profitability?
- KORU Medical Systems generated $45.1M in trailing twelve-month revenue with a net loss of $1.8M, representing a net margin of -4.0%. Gross margin stands at 62.4%, with free cash flow of -$1.1M. The latest reported period is Q2 2026.
- Who are KORU Medical Systems's competitors?
- KORU Medical Systems's key competitors include Baxter International Inc., Becton, Dickinson and Company, Scienture Holdings, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does KORU Medical Systems partner with?
- KORU Medical Systems's notable partners include Command Medical Products, Inc., CSL Behring, Takeda Pharmaceutical Company, and others.
- Where is KORU Medical Systems headquartered?
- KORU Medical Systems is headquartered in United States of America and employs approximately 82 people. It has been publicly traded since 1996.
